Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a significant decline in short interest in ...
Additionally, ART12.11, our innovative CBD-TMP cocrystal, is well positioned to begin clinical trials this year. Targeting ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Additionally, ART12.11, our innovative CBD-TMP cocrystal, is well positioned to begin clinical trials this year. Targeting anxiety and depression, ART12.11 offers a much-needed alternative to ...
Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and ...
Hosted on MSN28d
Artelo Biosciences reports promising nonclinical CBD studyArtelo Biosciences , Inc. (NASDAQ:ARTL), a clinical-stage biopharmaceutical company with a market capitalization of $4.5 million, announced nonclinical results for its proprietary cocrystal ...
Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, ...
After hours: March 7 at 5:50:14 p.m. EST Loading Chart for COCP ...
Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya Nab., Saint Petersburg 199034, Russian Federation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results